Physician profile
Robert J Steckmeyer
NPI 1104194638
$3,440.14
in general payments reported to CMS, 2019-2025
27 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.55 · 2022: $329 · 2023: $794 · 2024: $938 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,301.76 | 2022-2025 | |
| Novo Nordisk INC | $503.52 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.82 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $248.67 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $125.62 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $104.44 | 2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $95.28 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $92.85 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $88.12 | 2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $76.32 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $71.67 | 2024-2025 | |
| Lundbeck LLC | $60.89 | 2023-2024 | Rexulti |
| Sanofi Pasteur INC. | $60.58 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $51.26 | 2023-2025 | Uptravi, Opsumit |
| Indivior INC. | $31.50 | 2025 | Sublocade |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.89 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $20.58 | 2023 | Thinprep 2000 Processor |
| Corium, LLC | $19.22 | 2022 | |
| Viatris Specialty LLC | $19.17 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $15.93 | 2024 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $15.59 | 2023 | Strensiq |
| Amgen INC. | $15.46 | 2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $15.15 | 2023 | |
| Ascensia Diabetes Care US INC. | $15.10 | 2025 | |
| Insulet Corporation | $14.29 | 2024 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $13.30 | 2022 | |
| Neurocrine Biosciences, INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Steckmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.